Analyst Conference Summaries

Biotechnology Investor Aids

Celldex Therapeutics
CLDX

Conference date: May 7, 2019 Press Release Only

Celldex Breast Cancer Phase 2 Study of glembatumumab vedotin fails [April 16, 2018]

Celldex Value Depends on Coming Data [February 8, 2018 @ Seeking Alpha]

Celldex Set to Bounce Back [April 15, 2015 @ Seeking Alpha]

2019
Celldex
Q1 2019

     
May 7, 2019      
2018
Celldex
Q4 2018
May 10, 2018
August 8, 2018
Nov. 7, 2018
March 7, 2019
2017
May 9, 2017
August 8, 2017
Nov. 11, 2017
March 7, 2018
2016
05/05/2016
08/08/2016
11/07/2016
03/14/2017
2015

Celldex Q2
analyst call
not available  
08/10/2015
11/05/2015
02/25/2016

Celldex Therapeutics (CLDX) is a biotechnology company developing therapies for cancers.

Celldex Therapeutics web site


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMGN
 BIIB
 CLDX
 CELG
 EPZM
 GILD
 GLYC
 INO
 INCY
 ISRG
 MCHP
 MYL
 PLX
 REGN
 SGEN
 TTPH
 VBLT
 VSTM
 XLNX
 XLRN

 
 

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is investment journalism, not financial advice.

Copyright 2019 William P. Meyers